Skip to main content
SpringerLink
Log in

Drug costs for metastatic NSCLC stable, overall survival benefit poor

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Cramer-van der Welle CM, et al. Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014. PharmacoEconomics-Open : 12 Jun 2020. Available from: URL: https://doi.org/10.1007/s41669-020-00220-z

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Drug costs for metastatic NSCLC stable, overall survival benefit poor. PharmacoEcon Outcomes News 856, 14 (2020). https://doi.org/10.1007/s40274-020-6914-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6914-2

Search

Navigation